Page last updated: 2024-12-08
indisetron hydrochloride
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
indisetron hydrochloride: an anti-emetic agent, indisetron hydrochloride was developed in Japan; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 178038 |
| SCHEMBL ID | 15313306 |
| MeSH ID | M0484399 |
Synonyms (21)
| Synonym |
|---|
| indisetron hcl nisshin |
| indisetron hydrochloride |
| n-3389 |
| sinseron |
| sinseron (tn) |
| indisetron hydrochloride (jan) |
| D02632 |
| 160472-97-9 |
| n 3389 |
| unii-nbn3hb12dw |
| nbn3hb12dw , |
| 1h-indazole-3-carboxamide, n-(3,9-dimethyl-3,9-diazabicyclo(3.3.1)non-7-yl)-, dihydrochloride, endo- |
| 1h-indazole-3-carboxamide, n-((7-endo)-3,9-dimethyl-3,9-diazabicyclo(3.3.1)non-7-yl)-, dihydrochloride |
| indisetron hydrochloride [jan] |
| n-(endo-3,9-dimethyl-3,9-diazabicyclo(3.3.1)non-7-yl)-1h-indazole-3-carboxamide dihydrochloride |
| indisetron dihydrochloride |
| SCHEMBL15313306 |
| n-[(1s,5r)-3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl]-1h-indazole-3-carboxamide;dihydrochloride |
| n-[(1s,5r)-3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl]-1h-indazole-3-carboxamide;dihydrochloride. |
| I-175 |
| Q27284778 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " No serious adverse events were observed." | ( [The efficacy and safety of indisetron hydrochloride for the management of nausea/vomiting caused by chemotherapy for gynecologic cancer]. Emoto, M; Hachisuga, T; Kamura, T; Kawarabayashi, T; Kobayashi, H; Kotera, K; Masuzaki, H; Toki, N; Ushijima, K; Wake, N, 2008) | 0.64 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " We designed a pilot study in order to explore the optimal dosing period for indisetron during modified FOLFOX6 (mFOLFOX6)." | ( Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study. Asaka, M; Kato, K; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Muto, S; Nakatsumi, H; Oba, K; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2012) | 0.38 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.06
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.06) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (37.50%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 1 (12.50%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (37.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||